A cardiovascular stent is a small mesh tube that expands a narrowed or blocked coronary artery. Unfortunately, current stents, regardless metallic or polymeric, still largely fall short to the ideal clinical needs due to late restenosis, thrombosis and other clinical complications. Nonetheless, metallic stents are preferred clinically thanks to their superior mechanical property and radiopacity to their polymeric counterparts. The emergence of bioresorbable metals opens a window for better stent materials as they may have the potential to reduce or eliminate late restenosis and thrombosis. In fact, some bioresorbable magnesium (Mg)-based stents have obtained regulatory approval or under trials with mixed clinical outcomes. Some major issues with Mg include the too rapid degradation rate and late restenosis. To mitigate these problems, bioresorbable zinc (Zn)based stent materials are being developed lately with the more suitable degradation rate and better biocompatibility. The past decades have witnessed the unprecedented evolution of metallic stent materials from first generation represented by stainless steel (SS), to second generation represented by Mg, and to third generation represented by Zn. To further elucidate their pros and cons as metallic stent materials, we systematically evaluated their performances in vitro and in vivo through direct side-by-side comparisons. Our results demonstrated that tailored Zn-based material with proper configurations could be a promising candidate for a better stent material in the future.
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
Zn-based biomaterials
have emerged as promising new types of bioresorbable
metallics applicable to orthopedic devices, cardiovascular stents,
and other medical applications recently. Compared to other degradable
metallic biomaterials (i.e., Mg- or Fe-based), Zn biomaterials have
a more appropriate corrosion rate without hydrogen gas evolution.
Here, we evaluated the potential of Zn-based metallics as medical
implants, both in vitro and in vivo, alongside a standard benchmark
Mg alloy, AZ31. The mechanical properties of the pure Zn were not
strong enough but were significantly enhanced (microhardness >
70
kg/mm2, strength > 220 MPa, elongation > 15%) after
alloying
with Sr or Mg (1.5 at. %), surpassing the minimal design criteria
for load-bearing device applications. The corrosion rate of Zn-based
biomaterials was about 0.4 mm/year, significantly slower than that
of AZ31. The measured cell viability and proliferation of three different
human primary cells fared better for Zn-based biomaterials than AZ31
using both direct and indirect culture methods. Platelet adhesion
and activation on Zn-based materials were minimal, significantly less
than on AZ31. The hemolysis ratio of red cells (<0.5%) after incubation
with Zn-based materials was also well below the ISO standard of 5%.
Moreover, Zn-based biomaterials promoted stem cell differentiation
to induce the extracellular matrix mineralization process. In addition,
in vivo animal testing using subcutaneous, bone, and vascular implantations
revealed that the acute toxicity and immune response of Zn-based biomaterials
were minimal/moderate, comparable to that of AZ31. No extensive cell
death and foreign body reactions were observed. Taken together, Zn-based
biomaterials may have a great potential as promising candidates for
medical implants.
Energy and the environment are two of the main issues facing the world today. As a consequence abundant renewable green energy sources such as wave energy, have become hot topics. Here, a multiple‐frequency triboelectric nanogenerator based on the water balloon (WB‐TENG) is proposed for harvesting water wave energy in any direction. Owing to the high elasticity of the water balloon, the WB‐TENG can realize a multiple‐frequency response to low‐frequency external mechanical simulations to generate high‐frequency electrical output. In addition, the water balloon can achieve self‐support without any additional supporting structure because of its tension, to make WB‐TENG still produce electrical output under slight vibration, which can also bring high energy conversion efficiency. Moreover, the fabricated WB‐TENG generates a maximum instantaneous short‐circuit current and an open‐circuit voltage of 147 µA and 1221 V, respectively. Most noteworthy, under the same conditions, the total transferred charge of WB‐TENG is 28 times than that of traditional TENG based on double plate structure during one working cycle. Therefore, this design can provide an effective way to promote the development of TENGs in blue energy.
Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Porous synthetic grafts made of poly(glycerol sebacate) (PGS) can transform into autologous vascular conduits in vivo upon degradation of PGS. A long-held doctrine in tissue engineering is the necessity to match degradation of the scaffolds to tissue regeneration. Here, we tested the impact of degradation of PGS and its derivative in an interposition model of rat common carotid artery (CCA). Previous work indicates a complete degradation of PGS within approximately 2 weeks, likely at the fast end of the spectrum. Thus, the derivation of PGS focuses on delay degradation by conjugating the free hydroxy groups in PGS with a long chain carboxylic acid: palmitic acid, one of the most common lipid components. We evaluated two of the resultant palmitate-PGS (PPGS) in this study: one containing 9% palmitate (9-PPGS) and the other16% palmitate (16-PPGS). 16-PPGS grafts had the highest patency. Ultrasound imaging showed that the lumens of 16-PPGS grafts were similar to CCA and smaller than 9-PPGS and PGS grafts 12 weeks post-operation. Immunohistological and histological examination showed an endothelialized lumens in all three types of grafts within 4 weeks. Inflammatory responses to 16-PPGS grafts were limited to the adventitial space in contrast to a more diffusive infiltration in 9-PPGS and PGS grafts in week 4. Examination of calponin + and αSMA + cells revealed that 16-PPGS grafts remodeled into a distinctive bi-layered wall, while the walls of 9-PPGS grafts and PGS grafts only had one thick layer of smooth muscle-like cells. Correspondingly, the expression of collagen III and elastin displayed an identical layered structure in the remodeled 16-PPGS grafts, in contrast to a more spread distribution in 9-PPGS and PGS grafts. All the three types of grafts exhibited the same collagen content and burst pressure after 12 weeks of host remodeling. However, the compliance and elastin content of 16-PPGS grafts in week 12 were closest to those
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.